Risankizumab Use in Psoriatic Arthritis with Respiratory Comorbidities
Patient Selection and Monitoring
- The American Academy of Dermatology recommends using caution in patients with pre-existing immunosuppression-related conditions when considering risankizumab therapy, with a strength of evidence based on expert opinion 1
- Patients with bronchiectasis have increased susceptibility to respiratory infections, which may be a concern when using immunomodulatory therapies, and require more vigilant monitoring for respiratory symptoms and infections 2
- The European League Against Rheumatism (EULAR) guidelines recommend IL-23 inhibitors, such as risankizumab, for patients with clinically relevant skin involvement in psoriatic arthritis, with a high efficacy demonstrated in clinical trials 4, 5
- Baseline pulmonary function testing is recommended before initiating risankizumab therapy to establish a baseline respiratory status 2
Treatment Considerations
- The presence of bronchiectasis, asthma, and past smoking history modifies the risk-benefit assessment but does not contraindicate risankizumab use, according to the American Academy of Dermatology and Thorax guidelines 1, 2
- Consider prophylactic vaccination against pneumococcal and influenza infections before initiating therapy, as recommended by the Journal of the American Academy of Dermatology 6
- For patients with both psoriatic arthritis and significant skin involvement, IL-17 inhibitors are also recommended by EULAR guidelines as an alternative to risankizumab 4, 5
Implementation and Monitoring
- Establish baseline respiratory status with pulmonary function tests and ensure optimal management of underlying asthma and bronchiectasis before initiating risankizumab, as recommended by Thorax 2
- Schedule more frequent follow-up visits during the initial treatment period to monitor for respiratory symptoms, and educate the patient about promptly reporting any increase in respiratory symptoms or sputum production 2
- Consider collaboration between rheumatology and pulmonology for optimal management, as recommended by the Annals of the Rheumatic Diseases 4